WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 ("Reporting Period"):
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
HONG KONG/BEIJING (Reuters) -Hong Kong-listed shares of China's WuXi AppTec jumped as much as 9.8% on Monday after it said it has no links with any governments or their military organisations, and it should not be listed as a "biotechnology company of concern" in a draft U.S. bill. The drug research and development group said in a filing to the Shanghai Stock Exchange on Sunday that it has no human genomics business and does not collect human genome data in any of its existing businesses. A U.S. congressional committee focused on China has introduced a bill that would restrict federally funded medical providers from contracting WuXi AppTec and other Chinese biotech companies, citing WuXi AppTec's alleged military ties as part of the reason.